IL-3 dependence of a Thy-1lo, B220+, IL-3 receptor-positive antigen-specific DTH-initiating clone.
The elicitation of delayed-type hypersensitivity (DTH) reactions in mice is due to the sequential action of two different antigen-specific Thy-1+ cells. We have previously cloned the early-acting DTH-initiating cell from nude mice that were immunized and boosted by contact sensitization with oxazolone (OX). This clone WP-3.27 produces an antigen-specific factor, OX-F, that acts in an Ag-specific manner to initiate DTH. The clone was phenotyped as a Thy-1+, B220+, CD3-, CD4-, CD8- cell. In this report, we further detail the characteristics of this unusual Ag-specific DTH-initiating cell clone. By flow cytometry analysis, WP-3.27 is Thy-1lo, Lyt-1+ (CD5+), but CD3-, TCR-alpha beta-, and TCR-gamma delta-. Moreover, WP-3.27 does not express surface immunoglobulins but expresses B220 (CD45RA), and also some macrophage markers such as Mac-1, F4-80, and MHC class II after gamma-IFN treatment. Interestingly, this clone also expresses IL-3 receptors (IL-3R) and not IL-2R. In addition to the Ag-specific DTH-initiating factor, WP-3.27 constitutively produces IL-3. Inhibition of proliferation of WP-3.27 with an anti-mouse IL-3 monoclonal antibody suggests that the clone WP-3.27 is IL-3-dependent, at least partially. WP-3.27 also constitutively produces IL-1 and IL-6, but not TNF-alpha. LPS activation of the clone resulted in a net increase of IL-1, IL-6, and TNF-alpha production. Thus, this Ag-specific DTH-initiating cell clone makes a unique set of cytokines. Northern blot analysis demonstrated that clone WP-3.27 transcribes mRNA encoding IL-1, IL-3, IL-6, and TNF-alpha, but not for TNF-beta (lymphotoxin). The nature of this unusual cell, which displays characteristics of more than one cell lineage, is discussed.
Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut 06510.
I
I
Millet
N R
NR
Ferreri
R
R
Ramabhadran
P W
PW
Askenase
D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology; D015703:Antigens, CD / Q000032:analysis*; D000954:Antigens, Surface / Q000032:analysis*; D002999:Clone Cells; D006649:Histocompatibility Antigens / Q000032:analysis*; D006968:Hypersensitivity, Delayed / Q000209:etiology*; D007375:Interleukin-1 / Q000096:biosynthesis / Q000235:genetics; D007376:Interleukin-2 / Q000096:biosynthesis; D007377:Interleukin-3 / Q000502:physiology*; D015847:Interleukin-4 / Q000096:biosynthesis; D015850:Interleukin-6 / Q000096:biosynthesis / Q000235:genetics; D017493:Leukocyte Common Antigens; D008233:Lymphotoxin-alpha / Q000235:genetics; D008562:Membrane Glycoproteins / Q000032:analysis*; D051379:Mice; D010641:Phenotype; D016185:Receptors, Interleukin-3 / Q000032:analysis*; D018800:Thy-1 Antigens; D014158:Transcription, Genetic; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis
D000911:Antibodies, Monoclonal; D015703:Antigens, CD; D000954:Antigens, Surface; D006649:Histocompatibility Antigens; D007375:Interleukin-1; D007376:Interleukin-2; D007377:Interleukin-3; D015850:Interleukin-6; D008233:Lymphotoxin-alpha; D008562:Membrane Glycoproteins; D016185:Receptors, Interleukin-3; D018800:Thy-1 Antigens; D014409:Tumor Necrosis Factor-alpha; D015847:Interleukin-4; D017493:Leukocyte Common Antigens